ONO-AE3-208
(Synonyms: 4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸,AE 3-208;ONO AE3 208) 目录号 : GC15662
An EP4 receptor antagonist
Cas No.:402473-54-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ONO-AE3-208 is an inhibitor of EP4 [1].
EP4 is one of the prostaglandin E2 receptors and is associated with inflammatory disease and cancer such as prostate cancer. As an antagonist of EP4, ONO-AE3-208 is expected to be a potential therapy for prostate cancer. In vitro assays show that ONO-AE3-208 can suppress the migration and invasion of prostate cancer cells. 10μM of ONO-AE3-208 decreases wound healing proportion of PC3 and LNCaP cell lines in wound-healing assay. And in Transwell Invasion assay, ONO-AE3-208 inhibits cell invasion even at concentration of 0.1μM. ONO-AE3-208 is also reported to suppress bone metastasis in vivo [1].
Since activation of E2 can increase the expression of matrix metalloproteinase (MMP) and release inflammatory cytokines, and then exacerbates abdominal aortic aneurism (AAA) formation, ONO-AE3-208 is also used in the studies of AAA formation. It has been proved that ONO-AE3-208 can cause the elastic fiber degradation and inhibit AAA formation in vivo in a dose-dependent manner [2].
References:
[1] Song Xu, Zhengyu Zhang, Osamu Ogawa,Takeshi Yoshikawa, Hiromasa Sakamoto, Noboru Shibasaki, akayuki Goto, Liming Wang, Naoki Terada. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration and metastasis of prostate cancer. Cell Biochem Biophys. 2014, April.
[2] Utako Yokoyama, Ryo Ishiwata, Mei-Hua Jin, Yuko Kato, Orie Suzuki, Huiling Jin, Yasuhiro Ichikawa, Syun Kumagaya, Yuzo Katayama, Takayuki Fujita, Satoshi Okumura, Motohiko Sato, Yukihiko Sugimoto, Hiroki Aoki, Shinichi Suzuki, Munetaka Masuda, Susumu Minamisawa, Yoshihiro Ishikawa. Inhibition of EP4 Signaling Attenuates Aortic Aneurysm Formation. Plos One. 2012, May. 7, 5, e36724.
| Cas No. | 402473-54-5 | SDF | |
| 别名 | 4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸,AE 3-208;ONO AE3 208 | ||
| 化学名 | 4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic acid | ||
| Canonical SMILES | CC(C1=CC=C(C2=CC=CC=C21)F)C(=O)NC3=C(C=CC(=C3)C#N)CCCC(=O)O | ||
| 分子式 | C24H21FN2O3 | 分子量 | 404.43 |
| 溶解度 | ≥ 40.4 mg/mL in DMSO with gentle warming, ≥ 8.1 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4726 mL | 12.3631 mL | 24.7262 mL |
| 5 mM | 0.4945 mL | 2.4726 mL | 4.9452 mL |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4726 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。